Live Breaking News & Updates on Myelofibrosis treatment

Stay updated with breaking news from Myelofibrosis treatment. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

Texas , United-states , Houston , Naveen-pemmaraju , Department-of-leukemia , University-of-texas-md-anderson-cancer-center , Cancer-center , Navitoclax , Navitoclax-plus-ruxolotinib , Myelofibrosis , Ash , Ash-annual-meeting

COMING SOON: Advances in Myelofibrosis Treatment and Enhancing Patient Quality of Life

Christine Cooper, RN, BSN, provides a preview of an upcoming CURE Expert Connections program discussing advancements in the care of myelofibrosis, including improved outcomes and quality-of-life for patients.

Christine-cooper , Myelofibrosis-treatment , Enhancing-patient-quality , Cure , Cure-expert-connections , Mpns , Myelofibrosis , Myelofibrosis-care , Myelofibrosis-treatments , Myelofibrosis-treatment-advances ,

FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments

The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.

Jasper-morley , Myelofibrosis , National-organization-for-rare-disorders , About-myelofibrosis , National-organization , Rare-disorders , Drugs-intelligence-analyst , Orphan-drugs , Lood-cancer ,

Pelabresib Plus Jakafi Reduces Spleen Volume, Myelofibrosis Symptoms

Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” according to one expert.

North-carolina , United-states , California , New-york , Winston-salem , San-diego , American , John-mascarenhas , Rubena-mesa , Tisch-cancer-institute-at-mount-sinai , Drug-administration , Atrium-health-levine-cancer-center

Pelabresib Plus Ruxolitinib Improves Spleen Volume Reduction in JAK Inhibitor-Naive Myelofibrosis

Treatment with the combination of pelabresib and ruxolitinib led to a statistically significant and clinically meaningful improvement in spleen volume reduction vs placebo plus ruxolitinib in patients with JAK inhibitor-naive myelofibrosis, meeting the primary end point of the phase 3 MANIFEST-2 trial.

New-york , United-states , John-mascarenhas , Rubena-mesa , Tisch-cancer-institute-at-mount-sinai , European-medicines-agency , Dynamic-international-prognostic-scoring-system , Atrium-health-levine-cancer-center , Adult-leukemia-program , Tisch-cancer-institute , Mount-sinai , Manifest-2-trial

NCCN Guidelines Update Adds Momelotinib for High-, Low-Risk Myelofibrosis

Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia.

Women-health , Digital-health , Population-health , Nccn-guideline-updates , Momelotinib , Jak-inhibitors , Myelofibrosis , Rare-diseases ,

Increased Understanding of the Mechanisms of Myelofibrosis Helps Usher in New Treatments and Novel Agents

Gaby Hobbs, MD, discusses how research into the biology of myelofibrosis has propelled the development of novel therapies for this patient population and highlights the role that biomarkers play in the diagnosis, prognosis, and treatment response evaluation for these patients.

Boston , Massachusetts , United-states , Gaby-hobbs , Leukemia-service , Science-summit , Massachusetts-general-hospital , D , Myelofibrosis ,

FDA Approval of Momelotinib May Establish New SOC for Myelofibrosis With Anemia

Andrew T. Kuykendall, MD, discusses the importance of the approval of momelotinib in the treatment of patients with anemic symptomatic myelofibrosis, key efficacy and safety data from the MOMENTUM trial that supported the decision, and unanswered questions regarding the agent’s potential role in other subsets within this population.

Florida , United-states , Tampa , Andrewt-kuykendall , Glaxosmithkline , Malignant-hematology , Moffitt-cancer-center , Momelotinib , Fda , Fda-approval , Myelofibrosis

Newer-Generation JAK Inhibitors Expand Myelofibrosis Treatment Paradigm

Anthony M. Hunter, MD, discusses the roles for pacritinib, momelotinib, and fedratinib in patients with myelofibrosis; treatment sequencing with newer-generation JAK inhibitors after ruxolitinib; and the importance of having several treatment options in the second-line setting and beyond.

Georgia , United-states , Emory-university , Atlanta , Anthonym-hunter , Oncology-at-emory-university-school-of-medicine , Department-of-hematology , Medical-oncology , Emory-university-school , Immediate-care-center , Winship-cancer-institute

Advancing the Treatment Landscape for Patients With Myeloproliferative Neoplasms

This group of cancers remains a challenge to diagnose, can be rapidly progressive, and requires complex treatment and follow-up care, research suggests.

Texas , United-states , National-oncology-conference , World-health-organization , Association-of-community-cancer-centers , Community-cancer-centers , Oncology-conference , Rare-disease , Myeloproliferative-neoplasms , Myelofibrosis , Polycythemia-vera